Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Squibb : to Hold Virtual Three-Part Investor Series

share with twitter share with LinkedIn share with facebook
05/29/2020 | 07:00am EDT

Bristol Myers Squibb (NYSE: BMY) today announced that it will hold a virtual three part investor series during the week of June 22, 2020. Giovanni Caforio, M.D., chairman and chief executive officer, and members of the leadership team will discuss the Company’s strategy, pipeline and business opportunities.

Investors and the general public are invited to listen to the live audio webcast of the series at https://www.bms.com/investors or by dialing (866) 428-9517 (U.S. toll free) or (224) 357-2194 (International).

The three-part series will be held at 11:30 a.m. ET on each of the following dates:

Monday, June 22nd: Early Pipeline and Immuno-Oncology
Dial in confirmation code: 6872436

Thursday, June 25th: Hematology
Dial in confirmation code: 6996004

Friday, June 26th: Immunology and Cardiovascular
Dial in confirmation code: 7948849

Presentation materials will be available at the start of each live webcast. A replay and archived edition of the presentations will be available following each event. This series replaces the originally planned Investor Day that was postponed due to the COVID-19 pandemic.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
Latest news on BRISTOL-MYERS SQUIBB COMPA
07/06BRISTOL MYERS SQUIBB : Dragonfly Therapeutics Expands Collaboration With Bristol..
DJ
07/02BRISTOL-MYERS SQUIBB COMPANY : Ex-dividend day for
FA
06/29BRISTOL MYERS SQUIBB : European Commission Approves Reblozyl for the Treatment o..
AQ
06/29SELLAS Life Sciences Advancing Its Innovative Immunotherapy Across Phase 1, 2..
AQ
06/26BRISTOL MYERS SQUIBB : Immunology & Cardiovascular Presentation
PU
06/26BRISTOL MYERS SQUIBB : Myers, Acceleron Get EU Approval for Reblozyl
DJ
06/26BRISTOL MYERS SQUIBB : European Commission Approves Reblozyl (luspatercept) for ..
BU
06/26MERCK : Intensity Therapeutics Announces Publication of Research Reporting that ..
AQ
06/25BRISTOL MYERS SQUIBB : Investor Series Presentation
PU
06/22BRISTOL MYERS SQUIBB : Early Pipeline & Immuno-Oncology Presentation
PU
More news
Financials (USD)
Sales 2020 41 966 M - -
Net income 2020 1 114 M - -
Net Debt 2020 27 636 M - -
P/E ratio 2020 110x
Yield 2020 3,10%
Capitalization 131 B 131 B -
EV / Sales 2019
EV / Sales 2020 3,78x
Nbr of Employees 30 000
Free-Float 77,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 71,79 $
Last Close Price 57,89 $
Spread / Highest target 43,4%
Spread / Average Target 24,0%
Spread / Lowest Target 7,10%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Gerald L. Storch Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-9.81%130 987
JOHNSON & JOHNSON1.41%389 709
ROCHE HOLDING AG5.59%300 114
MERCK & CO., INC.-13.96%197 511
PFIZER, INC.-10.08%195 697
NOVARTIS AG-11.32%191 193